The lack of disclosed deal economics limits the immediate catalyst. Monitor for future 8-K filings or earnings calls that may reveal revenue-sharing terms or initial U.S. sales data.
Price Chart
Executive Summary
Immuron announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a medical device for digestive health. The deal expands Immuron's digestive health portfolio beyond Travelan® into a $4.16 billion U.S. market, but no financial terms (upfront payments, milestones, or revenue projections) were disclosed.
Key Facts
- Immuron executed an exclusive U.S. distribution agreement for PROIBS® with Calmino group AB.
- PROIBS® is a medical device for abdominal pain, bloating, and unsettled bowel movements, containing AVH200® from Aloe barbadensis Mill.
- The U.S. digestive/gut health supplement market is valued at $4.16 billion (Mordor Intelligence).
- No financial terms (upfront payments, milestones, or revenue projections) were disclosed in the press release.
- PROIBS® has been on the Swedish pharmacy market for more than a decade and was launched in Australia during FY26.
Financial Impact
Undisclosed — no upfront, milestone, or royalty terms provided
Risk Factors
- No financial terms disclosed — deal value and revenue contribution are unknown
- Immuron's market cap is only $9M, making the stock highly volatile on any news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3356450 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9200 (−3.06%) |
Oct 16, 2026 10d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9200 (−6.32%) |
Oct 13, 2026 13d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9200 (−11.54%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9200 (−26.69%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9200 (−48.89%) |
Aug 28, 2026 8w ago | 6-K | $1.15 | awaiting T+60 | — | $0.9200 (−20.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers